LONN.SW - Lonza Group AG
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 586.80 |
| Open | 585.20 |
| Bid | 0.00 x 0 |
| Ask | 577.20 x 0 |
| Day's Range | 576.40 - 587.60 |
| 52 Week Range | 436.80 - 595.00 |
| Volume | |
| Avg. Volume | 146,797 |
| Market Cap | 42.86B |
| Beta (5Y Monthly) | 0.62 |
| PE Ratio (TTM) | 34.61 |
| EPS (TTM) | 16.67 |
| Earnings Date | Jul 21, 2023 |
| Forward Dividend & Yield | 3.50 (0.61%) |
| Ex-Dividend Date | May 09, 2023 |
| 1y Target Est | 715.25 |
Fair Value
Related Research
Simply Wall St.Is Lonza Group AG's (VTX:LONN) Recent Performance Tethered To Its Attractive Financial Prospects?
Lonza Group's (VTX:LONN) stock is up by 6.2% over the past three months. Given its impressive performance, we decided...
- Simply Wall St.
Individual investors account for 56% of Lonza Group AG's (VTX:LONN) ownership, while institutions account for 44%
Key Insights Significant control over Lonza Group by individual investors implies that the general public has more...
- Simply Wall St.
Does Lonza Group (VTX:LONN) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
- Simply Wall St.
Lonza Group's (VTX:LONN) five-year earnings growth trails the impressive shareholder returns
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a...
American City Business JournalsThe Petri Dish: Blueprint hit with clinical hold, Moderna to set up patient assistance program
Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings.
- Simply Wall St.
Lonza Group Full Year 2022 Earnings: EPS Beats Expectations
Lonza Group ( VTX:LONN ) Full Year 2022 Results Key Financial Results Revenue: CHF6.22b (up 15% from FY 2021). Net...
ReutersEuropean stocks fall on earnings jitters, rate hike worries
(Reuters) -European stocks slipped on Wednesday as lacklustre results from U.S. software giant Microsoft fanned fears about the outlook for the tech sector, while investors remained concerned that central banks were not yet close to pausing their interest rate hikes. The pan-European STOXX 600 fell for a second day, closing down 0.3% but off a near two-week low hit earlier in the session. Technology shares, which have rebounded this year after a rough 2022, fell 0.4% as Microsoft forecast current-quarter cloud business revenue below estimates.
- Reuters
UPDATE 2-European stocks fall on earnings jitters, rate hike worries
European stocks slipped on Wednesday as lacklustre results from U.S. software giant Microsoft fanned fears about the outlook for the tech sector, while investors remained concerned that central banks were not yet close to pausing their interest rate hikes. The pan-European STOXX 600 fell for a second day, closing down 0.3% but off a near two-week low hit earlier in the session. Technology shares, which have rebounded this year after a rough 2022, fell 0.4% as Microsoft forecast current-quarter cloud business revenue below estimates.
ReutersLonza to buy back $2.17 billion worth of shares, backs mid-term growth
(Reuters) -Lonza on Wednesday said it will buy back shares worth 2 billion Swiss francs ($2.17 billion), despite an expected drop in annual margins, as the Swiss drug contract manufacturer backed its growth prospects for the near future. Lonza expects its 2023 core earnings before interest, depreciation and amortization, or EBITDA margin, to slip between 30% and 31%, down from 32.1% in 2022, as last year's boost from COVID-19 vaccine manufacturing services waned. The firm, which is in a multi-year investment push to assist drug developers as they bet on new therapeutic proteins, as well as cell and gene therapies, also reported an almost 20% jump in core 2022 EBITDA of 2.0 billion Swiss francs, slightly ahead of market expectations.
- Reuters
UPDATE 2-Lonza to buy back $2.17 bln worth of shares, backs mid-term growth
Lonza on Wednesday said it will buy back shares worth 2 billion Swiss francs ($2.17 billion), despite an expected drop in annual margins, as the Swiss drug contract manufacturer backed its growth prospects for the near future. Lonza expects its 2023 core earnings before interest, depreciation and amortization, or EBITDA margin, to slip between 30% and 31%, down from 32.1% in 2022, as last year's boost from COVID-19 vaccine manufacturing services waned. The firm, which is in a multi-year investment push to assist drug developers as they bet on new therapeutic proteins, as well as cell and gene therapies, also reported an almost 20% jump in core 2022 EBITDA of 2.0 billion Swiss francs, slightly ahead of market expectations.
- Simply Wall St.
Lonza Group AG's (VTX:LONN) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
With its stock down 9.8% over the past month, it is easy to disregard Lonza Group (VTX:LONN). However, stock prices are...
- Simply Wall St.
Institutions along with individual investors who hold considerable shares inLonza Group AG (VTX:LONN) come under pressure; lose 9.3% of holdings value
Every investor in Lonza Group AG ( VTX:LONN ) should be aware of the most powerful shareholder groups. We can see that...
Insider Monkey15 Biggest European Pharmaceutical Companies
In this piece, we will take a look at the 15 biggest European pharmaceutical companies. For more companies, head on over to 5 Biggest European Pharmaceutical Companies. Alongside the United States, Europe has some of the most advanced industries and economies in the world. While the Americans are rightly credited with having pioneered the modern […]
- Simply Wall St.
With EPS Growth And More, Lonza Group (VTX:LONN) Makes An Interesting Case
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
- Simply Wall St.
Lonza Group's (VTX:LONN) five-year total shareholder returns outpace the underlying earnings growth
It hasn't been the best quarter for Lonza Group AG ( VTX:LONN ) shareholders, since the share price has fallen 16% in...
- Reuters
UPDATE 1-Lonza's first-half core EBITDA gains 16.5%
Swiss drug contract manufacturer Lonza said first-half core earnings gained 16.5% on strong demand from biopharmaceutical companies. First-half core earnings - adjusted for interest, tax, depreciation and amortisation - (EBITDA) rose to 987 million Swiss francs ($1.02 billion), it said in a statement on Friday, beating an analyst consensus of about 940 million francs. For this year, Lonza said it was still targeting "low to mid-teens" sales growth, when excluding currency swings, as well as an improvement in the core EBITDA margin that is consistent with a 2024 goal of 33%-35%, up from 30.8% in 2021.
ReutersLonza's first-half core EBITDA gains 16.5%
(Reuters) -Swiss drug contract manufacturer Lonza said first-half core earnings gained 16.5% on strong demand from biopharmaceutical companies. First-half core earnings - adjusted for interest, tax, depreciation and amortisation - (EBITDA) rose to 987 million Swiss francs ($1.02 billion), it said in a statement on Friday, beating an analyst consensus of about 940 million francs. For this year, Lonza said it was still targeting "low to mid-teens" sales growth, when excluding currency swings, as well as an improvement in the core EBITDA margin that is consistent with a 2024 goal of 33%-35%, up from 30.8% in 2021.